The Web Health

Kanjinti

Generic Name: Trastuzumab [tra-TOO-zoo-mab].

Brand Names: Herceptin, Herzuma, Kanjinti, Ogivri, Ontruzant and Trazimera are a few of the medications available.

What is Kanjinti?

Kanjinti can be used to treat a variety of kinds of breast cancer or stomach cancer. Sometimes, it is used in conjunction with different cancer drugs. Kanjinti is often used in cases where cancer has spread to different parts of your body (metastatic). Kanjinti could be used for other purposes that are not mentioned in this guideline.

Side effects of Kanjinti

Contact a medical professional immediately. Get medical attention immediately if you notice symptoms that are warning signs of an allergic response, such as hives, difficulty breathing, or swelling of your lips, face, and tongue. There are some side effects that can happen after the injection. Inform your doctor immediately if you experience dizziness, fainting, nausea, weakness, or exhaustion, or if you experience a headache, fever, chills, or chest discomfort.

Kanjinti may cause serious side effects. Consult your physician immediately. If you suffer from:

  • A new ou is exacerbating the cough.
  • A feeling of lightheadedness that makes you feel like you've passed out.
  • Extreme headache with unfocused vision and pounding in your neck or ear.
  • The appearance of ulcers or blisters in your mouth; swelling or red gums; difficulty swallowing.
  • Heart issues: pounding heartbeats, nausea, swelling in your legs, weight gain that is rapid, being short of breath.
  • Low blood cell counts, fever, chills, tiredness, skin sores, simple bleeding, unusual bruises, white skin, cool fingers and toes, with a feeling of lightheadedness.
  • Signs of tumor cell breakdown—tiredness, weakness, muscle cramps, nausea, vomiting, diarrhea, a fast or slow heart rate, tingling in your hands and feet, or around your mouth.

The treatment for cancer may be delayed or discontinued permanently when you experience certain negative side effects.

Common adverse consequences of Kanjinti can be:

  • Heart-related problems.
  • Nausea, diarrhea, and weight loss.
  • Headache.
  • Sleep problems, fatigue.
  • Low blood cell count.
  • Rash.
  • Cough, chills, fever, or other indications of illness.
  • Mouth sores.
  • An altered sense of taste.
  • Cold symptoms like stuffy sinuses and a sore throat.

This isn't a complete list of all the side effects. Others could happen. Consult your physician to seek medical advice on adverse effects. You can report adverse reactions to the FDA at 1-800-FDA-1088.

Warnings

Do not take it if you're expecting. Use effective birth control and inform your doctor if you are pregnant while you are receiving treatment. Kanjinti could cause the heart to fail, particularly in the case of a heart condition or if you're taking other cancer medications. Certain side effects could be experienced when you inject. Tell your caregivers when you feel faint and nauseated, nauseous, lightheaded, weak, or exhausted, or if you experience a headache, fever, or chills.

Before you take this drug

Speak to your doctor if you are ever diagnosed with:

  • Heart disease.
  • Congestive heart failure.
  • A heart attack.
  • Allergies or breathing issues.

Kanjinti may cause heart failure, particularly in patients with heart disease who are also taking certain other cancer drugs (such as daunorubicin, doxorubicin, epirubicin, or idarubicin). You might need to undergo an unfavorable pregnancy test prior to commencing this treatment. Do not take Kanjinti if you are expecting. Kanjinti can cause injuries or even death to an unborn baby. Make sure you use effective birth control methods to stop pregnancy while taking this medication and for a minimum of 7 months following the last dose. Inform your doctor if you discover you are pregnant. If you become pregnant while taking Kanjinti in the first 7 months after the last dose, your name might be placed on a pregnancy registry in order to monitor the effect of the drug on the child. It is not recommended to breastfeed during this medication or for at least 7 months following the last dose. Consult your physician regarding any risks.

How to take Kanjinti?

Your doctor will conduct an examination to make sure that Kanjinti is a suitable medicine to treat cancer. Kanjinti is administered as an injection into a vein. Your healthcare professional will offer you the injection. Kanjinti is usually prescribed once a week for 1 or 3 weeks. Follow the instructions of your doctor for dosing extremely carefully. The medicine should be administered slowly, and infusions can take as long as 90 minutes to complete.

It is possible that you will require frequent medical tests to ensure that the medicine isn't creating harmful side effects. Your treatment for cancer could be delayed, depending on the results. Your heart's function could need to be assessed prior to and during your treatment using Kanjinti. It is also possible to have a test for heart function every six months for two years following the last dose of this medication. Kanjinti is typically prescribed for 52 weeks, or until your body's response to the medicine ceases.

What happens if I miss a dose?

Contact your doctor for advice in the event that you don't make an appointment to see your Kanjinti.

What happens if I overdose?

For medical emergencies, seek emergency medical attention or contact the Poison Help line at 1-800-222-1222.

 What should be avoided?

Follow the instructions of your physician regarding any limitations on foods, drinks, or any activity.

Interaction with other drugs

Other medications can impact Kanjinti, such as medications that are prescribed and available over the counter, vitamins, and herbal products. Inform your physician about all the medicines you are currently taking as well as any medications you are about to start or stop taking. Kanjinti may have long-lasting consequences for your heart, specifically when you are taking other cancer medications. At least seven months after the final dose of trastuzumab, inform your doctor treating you that you've used Kanjinti.